Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Hematol Oncol Clin North Am. 2018 Feb;32(1):75–88. doi: 10.1016/j.hoc.2017.09.007

Table 1.

Treatments for KSHV-MCD

Therapy Dose Mechanism of action When to use
Rituximab 375 mg/m2 weekly x4 weeks Depletes IL-6 secreting CD20+ B cells Mild symptomatic disease
Rituximab + Rituximab 375 mg/m2 Addition of cytotoxic Aggressive
liposomal doxorubicin + liposomal doxorubicin 20 mg/m2 every 3 weeks until response plateau chemotherapy to treat CD20 negative MCD plasmablasts and KS spindle cells disease and/or concurrent KS
Rituximab + etoposide Rituximab 375 mg/m2 + etoposide 100 mg/m2 IV weekly x4 weeks Addition of cytotoxic chemotherapy to treat CD20 negative MCD plasmablasts Aggressive disease
Zidovidine (AZT) + valganciclovir Zidovidine 600 mg PO every 6 hours + valganciclovir 900 mg PO every 12 hours days 1–7 of 21-day cycle Virus activated cytotoxic therapy Mild disease with concurrent KS and/or patients allergic to rituximab